Patents Assigned to Five Eleven Pharma Inc.
  • Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application
    Patent number: 11071794
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: July 27, 2021
    Assignee: Five Eleven Pharma Inc.
    Inventors: Zehui Wu, Zhihao Zha, Futao Liu, Karl Ploessl, Seok Rye Choi, Hank F. Kung
  • Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application
    Patent number: 10912849
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: February 9, 2021
    Assignee: FIVE ELEVEN PHARMA INC.
    Inventors: Zehui Wu, Zhihao Zha, Futao Liu, Karl Ploessl, Seok Rye Choi, Hank F. Kung
  • NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION
    Publication number: 20200230263
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 23, 2020
    Applicant: Five Eleven Pharma Inc.
    Inventors: Zehui WU, Zhihao ZHA, Futao LIU, Karl PLOESSL, Seok Rye CHOI, Hank F. KUNG
  • Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
    Patent number: 10688200
    Abstract: The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: June 23, 2020
    Assignee: FIVE ELEVEN PHARMA INC.
    Inventors: Hank F. Kung, Karl Ploessl, Seok Rye Choi, Zhihao Zha, Zehui Wu
  • HBED-bisphosphonates, radiometal conjugates and their use as theranostic agents
    Patent number: 10253052
    Abstract: The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled with 68Ga displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: April 9, 2019
    Assignee: Five Eleven Pharma Inc.
    Inventors: Hank F. Kung, Zehui Wu, Seok Rye Choi, Karl Plössl, Zhihao Zha
  • HBED-Bisphosphonates, Radiometal Conjugates and Their Use as Theranostic Agents
    Publication number: 20170022224
    Abstract: The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled with 68Ga displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 6, 2016
    Publication date: January 26, 2017
    Applicant: Five Eleven Pharma Inc.
    Inventors: Hank F. KUNG, Zehui Wu, Seok Rye Choi, Karl PLÖSSL, Zhihao Zha